시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 HER2 양성 유방암 시장 보고서(2025년)
HER2-Positive Breast Cancer Global Market Report 2025
상품코드 : 1717034
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,319,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,134,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,949,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

HER2 양성 유방암 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 7.08%의 연평균 복합 성장률(CAGR)로 144억 1,000만 달러에 달할 것으로 예측됩니다. 향후 비침습적 모니터링을 위한 액체생검 수요 증가, 병용요법 채택 증가, 면역요법 및 신약에 대한 관심 증가, 액체생검 기술 활용 확대 등의 요인이 예측 기간 동안 성장을 견인할 것으로 보입니다. 또한, 전문 암 치료 센터 증가는 이러한 성장에 기여하고 있습니다. 예측 기간 동안 주요 동향으로는 표적 치료의 발전, 신약 처방, 면역치료 접근법의 혁신, 새로운 HER2 표적 치료제의 개발, 환자 분류를 개선하기 위한 바이오마커의 발전 등을 들 수 있습니다.

HER2 양성 유방암 시장은 면역요법의 채택 확대가 큰 폭의 성장을 견인할 것으로 예측됩니다. 면역요법은 암을 포함한 질병과 싸우는 면역체계의 자연적 능력을 향상시키거나 변형시키는 치료법입니다. 면역요법은 면역체계가 암세포를 식별하고 제거하는 능력을 강화하여 기존 치료법에 비해 효능을 높이고 부작용을 줄임으로써 효과를 발휘하며, HER2 양성 유방암의 경우 면역요법은 면역체계가 HER2 과발현 암세포를 표적으로 공격할 수 있도록 하여 환자의 예후를 개선하고 재발의 위험을 감소시킵니다. 환자의 예후를 개선하고 재발 위험을 줄이는 데 도움이 됩니다. 미국암연구협회에 따르면, 2023년 FDA는 11종의 면역관문억제제(ICI)를 승인했으며, 최소 1종은 20개의 서로 다른 암종과 특정 분자 마커를 가진 고형암 치료제로 승인되었습니다. 이러한 면역 치료의 강력한 채택이 HER2 양성 유방암 시장의 확대에 기여하고 있습니다.

HER2 양성 유방암 치료제 시장은 치료 효과와 환자 예후를 개선할 수 있는 혁신적인 치료법 개발에 집중하고 있습니다. HER2를 표적으로 하는 항체와 세포독성 약물을 결합하여 HER2 양성 암세포에 직접 약물을 전달함으로써 보다 정확하고 효과적인 치료를 실현하는 HER2 지향성 항체-약물 복합체(ADC)가 그 중 하나입니다. 예를 들어, 2024년 1월 아스트라제네카 인도 제약사는 다이이찌산쿄와 공동 개발한 HER2 지향성 ADC인 트라스투주맙-델크스테칸을 출시했습니다. 트라스투주맙 델크스테칸은 HER2 양성 암세포를 표적으로 하여 세포독성 약물을 해당 부위에 직접 전달함으로써 보다 표적화된 치료 효과를 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

LSH
영문 목차

영문목차

HER2-positive breast cancer is a form of breast cancer distinguished by an excess of the human epidermal growth factor receptor 2 (HER2) protein. This protein accelerates the growth of cancer cells and is present in about 15-20% of breast cancer cases. Generally, HER2-positive breast cancer tends to be more aggressive compared to HER2-negative types but can be treated using targeted therapies that block HER2 activity.

The primary treatment options for HER2-positive breast cancer include targeted therapy, chemotherapy, endocrine therapy, immunotherapy, and other methods. Targeted therapy is a treatment that specifically targets certain molecules, such as proteins or genes that drive cancer growth, while minimizing damage to healthy cells. These medications can be administered through different methods, including intravenous, oral, and other routes. They are distributed through various outlets such as hospital pharmacies, retail pharmacies, and online platforms, and are utilized by different end users such as hospitals, home care services, specialty clinics, and more.

The HER2-positive breast cancer market research report is one of a series of new reports from The Business Research Company that provides HER2- positive breast cancer market statistics, including the HER2- positive breast cancer industry global market size, regional shares, competitors with the HER2- positive breast cancer market share, detailed HER2- positive breast cancer market segments, market trends, and opportunities, and any further data you may need to thrive in the HER2- positive breast cancer industry. This HER2- positive breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The HER2-positive breast cancer market size has grown strongly in recent years. It will grow from $10.21 billion in 2024 to $10.96 billion in 2025 at a compound annual growth rate (CAGR) of 7.34%. The growth observed during the historical period can be linked to factors such as the increasing rates of early detection and diagnosis, greater awareness of HER2-positive subtypes, rising investments in research and development, the growing adoption of precision medicine, and a heightened focus on enhancing patient outcomes.

The HER2-positive breast cancer market size is expected to see strong growth in the next few years. It will grow to $14.41 billion in 2029 at a compound annual growth rate (CAGR) of 7.08%. Looking ahead, growth in the forecast period is expected to be driven by factors such as the rising demand for liquid biopsy for non-invasive monitoring, the increasing adoption of combination therapies, a growing emphasis on immunotherapies and novel drug formulations, and the expanding use of liquid biopsy techniques. Additionally, the rising number of specialized cancer treatment centers is contributing to this growth. Key trends in the forecast period include advancements in targeted therapies, new drug formulations, innovations in immunotherapy approaches, the development of novel HER2-targeted therapies, and progress in biomarkers to improve patient stratification.

The growing adoption of immunotherapy is expected to drive significant growth in the HER2-positive breast cancer market. Immunotherapy is a treatment that boosts or modifies the immune system's natural ability to fight diseases, including cancer. It works by enhancing the immune system's capacity to identify and eliminate cancer cells, offering improved efficacy and fewer side effects compared to traditional treatments. For HER2-positive breast cancer, immunotherapy helps by enabling the body's immune system to target and attack HER2-overexpressing cancer cells, improving patient outcomes and reducing the risk of recurrence. According to the American Association for Cancer Research, in 2023, the FDA approved 11 immune checkpoint inhibitors (ICIs), with at least one authorized for the treatment of 20 different cancer types and for any solid tumor with specific molecular markers. This strong adoption of immunotherapy is helping to expand the HER2-positive breast cancer market.

Companies in the HER2-positive breast cancer market are focused on developing innovative therapies to improve treatment efficacy and patient outcomes. One such therapy is HER2-directed antibody-drug conjugates (ADCs), which combine antibodies targeting HER2 with cytotoxic drugs, delivering the drug directly to HER2-positive cancer cells for more precise and effective treatment. For example, in January 2024, AstraZeneca India Pharma Ltd. launched Trastuzumab deruxtecan, a HER2-directed ADC developed in collaboration with Daiichi Sankyo. Trastuzumab deruxtecan targets HER2-positive cancer cells and delivers a cytotoxic drug directly to the site, offering a more targeted approach to treatment.

In May 2023, Roche Holding AG, a Switzerland-based pharmaceutical company, acquired the rights to Zion Pharma's lead program, ZN-A-1041, for an undisclosed amount. This acquisition aims to accelerate the development and commercialization of ZN-A-1041, a blood-brain-barrier-penetrant HER2 inhibitor designed to treat brain metastases in HER2-positive breast cancer patients. Zion Pharma, based in China, specializes in developing drugs for HER2-positive breast cancer, and this collaboration with Roche focuses on advancing treatment options for patients with brain metastases, a common complication in HER2-positive breast cancer.

Major players in the her2-positive breast cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co. Ltd., Incyte Corporation, BioNTech SE, MacroGenics Inc., CStone Pharmaceuticals Co. Ltd., Sorrento Therapeutics Inc., Syndax Pharmaceuticals Inc., Fate Therapeutics Inc., Ambrx Biopharma Inc.

North America was the largest region in the HER2- positive breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in HER2- positive breast cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the HER2- positive breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The HER2-positive breast cancer market consists of sales of small molecule inhibitors, antibody-drug conjugates, and monoclonal antibodies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

HER2-Positive Breast Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on her2-positive breast cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for her2-positive breast cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The her2-positive breast cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. HER2-Positive Breast Cancer Market Characteristics

3. HER2-Positive Breast Cancer Market Trends And Strategies

4. HER2-Positive Breast Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global HER2-Positive Breast Cancer Growth Analysis And Strategic Analysis Framework

6. HER2-Positive Breast Cancer Market Segmentation

7. HER2-Positive Breast Cancer Market Regional And Country Analysis

8. Asia-Pacific HER2-Positive Breast Cancer Market

9. China HER2-Positive Breast Cancer Market

10. India HER2-Positive Breast Cancer Market

11. Japan HER2-Positive Breast Cancer Market

12. Australia HER2-Positive Breast Cancer Market

13. Indonesia HER2-Positive Breast Cancer Market

14. South Korea HER2-Positive Breast Cancer Market

15. Western Europe HER2-Positive Breast Cancer Market

16. UK HER2-Positive Breast Cancer Market

17. Germany HER2-Positive Breast Cancer Market

18. France HER2-Positive Breast Cancer Market

19. Italy HER2-Positive Breast Cancer Market

20. Spain HER2-Positive Breast Cancer Market

21. Eastern Europe HER2-Positive Breast Cancer Market

22. Russia HER2-Positive Breast Cancer Market

23. North America HER2-Positive Breast Cancer Market

24. USA HER2-Positive Breast Cancer Market

25. Canada HER2-Positive Breast Cancer Market

26. South America HER2-Positive Breast Cancer Market

27. Brazil HER2-Positive Breast Cancer Market

28. Middle East HER2-Positive Breast Cancer Market

29. Africa HER2-Positive Breast Cancer Market

30. HER2-Positive Breast Cancer Market Competitive Landscape And Company Profiles

31. HER2-Positive Breast Cancer Market Other Major And Innovative Companies

32. Global HER2-Positive Breast Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The HER2-Positive Breast Cancer Market

34. Recent Developments In The HER2-Positive Breast Cancer Market

35. HER2-Positive Breast Cancer Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기